<- Go Home
BELLUS Health Inc.
As of June 28, 2023, BELLUS Health Inc. was acquired by GSK plc. BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.
Market Cap
CAD 1.9B
Volume
126.0K
Cash and Equivalents
CAD 85.4M
EBITDA
-CAD 90.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CAD 15.0K
Profit Margin
100.00%
52 Week High
CAD 15.02
52 Week Low
CAD 6.48
Dividend
N/A
Price / Book Value
5.05
Price / Earnings
-20.40
Price / Tangible Book Value
5.84
Enterprise Value
CAD 1.6B
Enterprise Value / EBITDA
-17.32
Operating Income
-CAD 90.3M
Return on Equity
26.76%
Return on Assets
-16.70
Cash and Short Term Investments
CAD 313.0M
Debt
CAD 1.2M
Equity
CAD 368.9M
Revenue
CAD 15.0K
Unlevered FCF
-CAD 54.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium